Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
NodThera is developing a portfolio of novel, potent and selective NLRP3 inflammasome inhibitors, with one clinical-stage candidate and several others in preclinical development. The company is seeking partners to advance its programs through clinical development in a range of indications.
CalciMedica, a clinical-stage biopharma company, is developing potentially first-in-class small molecules to combat excessive intracellular calcium levels that drive pathological processes in inflammatory diseases and acute injury, including COVID-19.
Reacta Healthcare produces pharmaceutical grade oral food challenges (OFCs) for diagnosing and establishing the severity of food allergies. The company’s standardized OFC for peanut is currently used in clinical trials of food allergy therapies in the UK, EU, and North America.
Targeting allergies and beyond, biotechnology company Angany is combining immunotherapy and anti-viral approaches for the development of innovative eBioparticles designed to increase immunogenicity and decrease allergenicity.
Switzerland-based Rejuveron is building a portfolio of innovative subsidiary companies that are all dedicated to discovering therapies to promote healthy aging.
Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B and to programs that target retinal cells.
With its lead phase 3 candidate Nefecon in development for the treatment of primary immunoglobulin A nephropathy and a late-stage orphan focused NOX program, Calliditas Therapeutics is pioneering new rare-disease therapies.
With its multi-functional drug discovery engine that combines digital and human-based platforms, such as AnalytiX and microOrgan, Vyant Bio is accelerating the drug discovery process from ID to IND.
In the past decade, deals involving rare diseases have increased in size and value, supported by the growing number of opportunities based on novel therapeutic platforms.
Global biotechnology company BioMarin focuses on developing and commercializing innovative therapies through a range of modalities. The company’s diverse pipeline, spanning exploratory to marketed programs, relies heavily on its genetic and genomic expertise, manufacturing capabilities, and long-term partnering models.
With its Healnet platform, Healx pairs cutting-edge AI with industry-leading drug discovery and rare disease expertise to identify new uses for known compounds. The company now has over 20 programs in development.
Seattle’s SEngine is using patient tumor samples to derive cancer organoids for accurate ex vivo drug testing, target identification and drug development.
Northern Antibiotics is developing improved versions of polymyxins to help fight against resistant Gram-negative bacteria and has three parallel programs in development.
The Swiss pharmaceutical company BioVersys is developing next-generation antimicrobial drugs with unique modes of action targeting a range of multidrug-resistant bacteria.
Lysando AG’s Artilysin platform technology is producing novel antimicrobial proteins with a unique mode of action and a wide range of applications, from human and veterinary medicine to the food and cosmetics industry. Lysando is licensing the technology to companies all around the world.
